Business Context and Reporting Period
Company: American BriVision (Holding) Corporation (Note: Input metadata references "ABVC BIOPHARMA, INC.", but the filing text identifies the registrant as American BriVision (Holding) Corporation).
Filing Type: Form 8-K (Current Report)
Reporting Date: September 5, 2019 (Earliest event reported: August 28, 2019)
Event: Entry into a Material Definitive Agreement involving the issuance of a convertible promissory note to an accredited investor.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial statements. Key metrics related to the transaction include:
- Gross Proceeds Raised: $200,000
- Instrument: Convertible Promissory Note
- Principal Amount: $200,000
- Interest Rate: 20% per annum
- Maturity Date: August 27, 2020
- Conversion Price: Lower of $0.50 per share or 70% of the per share offering price of a future public equity offering exceeding $10,000,000.
- Ownership Limitation: Conversion is restricted if the holder would beneficially own more than 4.99% of outstanding common stock.
Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, operating margins, total debt, or liquidity ratios outside of this specific transaction.
Material Changes
The filing discloses the creation of a direct financial obligation of $200,000 and the unregistered sale of equity securities (via the convertible note). There is no comparative period data provided in this document to assess changes in operational performance versus prior periods.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the execution of a Securities Purchase Agreement (SPA) and the issuance of the Note to secure capital.
Risks and Contingencies:
- Debt Obligation: The company has incurred a liability due in one year with a high interest rate (20%).
- Dilution Risk: Future conversion of the note into common stock will dilute existing shareholders, subject to the 4.99% beneficial ownership limitation.
- Conversion Trigger: The conversion price is contingent on a future public equity offering exceeding $10,000,000, which has not yet occurred.
Investor Verification Checklist
- Verify the current cash position of American BriVision (Holding) Corporation to assess ability to service the 20% interest and $200,000 principal by August 2020.
- Confirm the total number of shares currently issued and outstanding to calculate the potential dilution impact of the 4.99% conversion cap.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 10.2) for additional covenants or default provisions.
- Investigate the company's progress toward a public equity offering exceeding $10,000,000, as this determines the conversion price.
- Clarify the discrepancy between the metadata company name ("ABVC BIOPHARMA, INC.") and the registrant name in the filing ("American BriVision (Holding) Corporation").